Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6191MR)

This product GTTS-WQ6191MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6191MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9050MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ7618MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ418MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ12836MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ6080MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ10167MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ13971MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ13176MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW